Arachidonic acid supplementation to improve cognitive impairment of schizophrenia

Not Applicable

• Conditions: Schizophrenia; Mental and Behavioural Disorders

• Registration Number: ISRCTN31248612
• Lead Sponsor: ational Natural Science Foundation of China

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-05
• Last Update Posted: 9 September 2024
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

1. Patients of SZ were diagnosed according to the International Classification of Diseases 10th edition (ICD-10)
2. The patient's family members or legal guardians fully understood the content of this study and signed informed consent

Exclusion Criteria

1. Patients should not have a history of other mental disorders, neurological disorders, serious physical diseases, traumatic brain injury, substance abuse, or dependence
2. Healthy controls should not have any current or previous psychiatric history or family history, as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function was measured using the Cambridge Neuropsychological Test Automated Battery® (CANTAB®) system at baseline, week 3, and 6

Secondary Outcome Measures

Name	Time	Method
1. RBC's lipids and fatty acids were measured using gas chromatography-mass spectrometry at baseline and week 6<br>2. Mitochondria lipids measured using ultrahigh-performance liquid chromatography quadrupole orbitrap mass spectrometry at baseline and endpoint<br>3. RNA sequencing of white blood cells was conducted at baseline and endpoint<br>4. Niacin skin flushing response test using 6 concentrations (triple gradient dilution from 60 mM) of niacin dropped onto the skin at baseline, week 3, and 6